Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

BACKGROUND: Remdesivir is approved for treatment of coronavirus disease 2019 (COVID-19) in nonhospitalized and hospitalized adult and pediatric patients. Here we present severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resistance analyses from the phase 3 ACTT-1 randomized placebo-contro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hedskog, Charlotte, Rodriguez, Lauren, Roychoudhury, Pavitra, Huang, Meei-Li, Jerome, Keith R, Hao, Linhui, Ireton, Renee C, Li, Jiani, Perry, Jason K, Han, Dong, Camus, Gregory, Greninger, Alexander L, Gale, Michael, Porter, Danielle P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629708/
https://www.ncbi.nlm.nih.gov/pubmed/37466213
http://dx.doi.org/10.1093/infdis/jiad270

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629708/
https://www.ncbi.nlm.nih.gov/pubmed/37466213
http://dx.doi.org/10.1093/infdis/jiad270

Ejemplares similares